组织病理学家在临床试验中的重要作用:挑战与应对方法
本文阐述组织病理学家在临床试验全流程中的关键作用,包括生物标志物评估、组织获取和周转时间等,指出新辅助治疗标本复杂评估和最小数据集扩展增加所有病理学家工作量,而全球病理学家和生物医学科学家短缺背景下需提供资金、教育、培训和行政支持,并特别介绍英国模型和CM-Path倡议。
要点
- 组织病理学家参与临床试验从概念设计到结果传播的全过程。
- 新辅助治疗标本复杂评估和最小数据集扩展增加所有病理学家工作量。
- 基层试验病理支持需资金、教育、培训及生物医学科学家和行政支持。
核心结论
- 组织病理学家输入对临床试验各阶段至关重要,需资金、教育、培训和行政支持以应对额外需求。
研究设计与样本
- 本文为综述性文章,讨论组织病理学家在临床试验中的参与方式、挑战及应对策略,特别强调英国模型和CM-Path倡议。
主要发现
- 组织病理学家日常工作对临床试验有宝贵贡献但常未被认可。
- 新辅助治疗标本复杂评估和不断扩展的最小数据集增加所有病理学家工作量。
- 临床试验支持面临工作量压力增加和全球病理学家及生物医学科学家短缺的背景。
临床怎么用
- 组织病理学家应在研究概念开发、研究设计、试验实施、分析和结果传播各阶段提供输入。
- 基层试验病理支持需确保资金用于病理学家时间、教育、培训、生物医学科学家和行政支持。
- 需提高对组织病理学贡献的认可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-quality histopathology is essential for the success of clinical trials. Histopathologists have a detailed understanding of tumour biology and mechanisms of disease, as well as practical knowledge of optimal tissue handling and logistical service requirements for study delivery, such as biomarker evaluation, tissue acquisition and turnaround times. As such, histopathologist input is essential throughout every stage of research and clinical trials, from concept development and study design to trial delivery, analysis and dissemination of results. Patient recruitment to trials takes place among all healthcare settings, meaning that histopathologists make an invaluable contribution to clinical trials as part of their routine day-to-day work that often goes unrecognised. More complex evaluation of surgical specimens in the neoadjuvant setting and ever-expanding minimum data sets add to the workload of every histopathologist, not just academic pathologists in tertiary centres. This is occurring against a backdrop of increasing workload pressures and a worldwide shortage of histopathologists and biomedical scientists. Providing essential histopathology support for trials at grassroots level requires funding for adequate resources including histopathologist time, education and training, biomedical scientist and administrative support and greater recognition of the contribution made by histopathology. This paper will discuss the many ways in which histopathologists are involved in clinical trials and the challenges faced in meeting the additional demands posed by trial participation and potential ways to address this, with a special emphasis on the UK model and the Cellular-Molecular Pathology Initiative (CM-Path).
引用
- Provenzano E, Driskell OJ, O'Connor DJ, et al. The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology. 2020. PMID: 32145084. doi:10.1111/his.14099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。